Lantheus Shares Dip Following Uncertain FDA Approval Outlook

Lantheus Holdings shares are trading lower after the FDA set a lengthy timeline for the potential approval of its new PSMA PET imaging agent formulation, raising concerns about future regulatory challenges and market entry delays.